C Proudlove

681 total citations
15 papers, 466 citations indexed

About

C Proudlove is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Otorhinolaryngology. According to data from OpenAlex, C Proudlove has authored 15 papers receiving a total of 466 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Pulmonary and Respiratory Medicine, 5 papers in Surgery and 3 papers in Otorhinolaryngology. Recurrent topics in C Proudlove's work include Lung Cancer Treatments and Mutations (6 papers), Antiplatelet Therapy and Cardiovascular Diseases (3 papers) and Lung Cancer Diagnosis and Treatment (3 papers). C Proudlove is often cited by papers focused on Lung Cancer Treatments and Mutations (6 papers), Antiplatelet Therapy and Cardiovascular Diseases (3 papers) and Lung Cancer Diagnosis and Treatment (3 papers). C Proudlove collaborates with scholars based in United Kingdom. C Proudlove's co-authors include Angela Boland, A Bagust, Y Dündar, J Greenhalgh, Rumona Dickson, Nigel Fleeman, C McLeod, Jo Hockenhull, S.F.M. Grimmer and DJ Back and has published in prestigious journals such as British Journal of Clinical Pharmacology, Health Technology Assessment and PharmacoEconomics.

In The Last Decade

C Proudlove

15 papers receiving 447 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
C Proudlove United Kingdom 11 126 99 64 60 60 15 466
Agnes L. F. Chan Taiwan 17 176 1.4× 212 2.1× 23 0.4× 107 1.8× 54 0.9× 56 710
Frédérique Rousseau France 14 156 1.2× 421 4.3× 53 0.8× 78 1.3× 55 0.9× 60 744
Kim Saverno United States 11 139 1.1× 66 0.7× 35 0.5× 42 0.7× 117 1.9× 29 500
Aimee Faso United States 7 70 0.6× 152 1.5× 68 1.1× 95 1.6× 31 0.5× 8 541
Kui Huang United States 13 38 0.3× 97 1.0× 65 1.0× 46 0.8× 50 0.8× 29 613
Trine Lembrecht Jørgensen Denmark 12 156 1.2× 409 4.1× 90 1.4× 120 2.0× 89 1.5× 41 764
Lesley Wise United Kingdom 9 58 0.5× 219 2.2× 19 0.3× 71 1.2× 49 0.8× 12 480
Sophie Fédrizzi France 13 172 1.4× 358 3.6× 42 0.7× 73 1.2× 19 0.3× 49 727
Sheray N. Chin Jamaica 11 99 0.8× 208 2.1× 36 0.6× 115 1.9× 33 0.6× 23 479
James Chan United States 18 87 0.7× 139 1.4× 44 0.7× 71 1.2× 141 2.4× 29 947

Countries citing papers authored by C Proudlove

Since Specialization
Citations

This map shows the geographic impact of C Proudlove's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C Proudlove with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C Proudlove more than expected).

Fields of papers citing papers by C Proudlove

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C Proudlove. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C Proudlove. The network helps show where C Proudlove may publish in the future.

Co-authorship network of co-authors of C Proudlove

This figure shows the co-authorship network connecting the top 25 collaborators of C Proudlove. A scholar is included among the top collaborators of C Proudlove based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C Proudlove. C Proudlove is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
2.
Greenhalgh, J, A Bagust, Angela Boland, et al.. (2011). Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of Technology Appraisal No. 90): a systematic review and economic analysis. Health Technology Assessment. 15(31). 1–178. 25 indexed citations
3.
Bagust, A, J Greenhalgh, Angela Boland, et al.. (2010). Cetuximab for Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck. PharmacoEconomics. 28(6). 439–448. 36 indexed citations
4.
Brown, Tamara, Angela Boland, A Bagust, et al.. (2010). Gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer. Health Technology Assessment. 14(Suppl 2). 71–79. 50 indexed citations
5.
Greenhalgh, J, A Bagust, Angela Boland, et al.. (2010). Prasugrel for the treatment of acute coronary artery syndromes with percutaneous coronary intervention. Health Technology Assessment. 14(Suppl 1). 31–38. 3 indexed citations
6.
Brown, Tamara, Angela Boland, A Bagust, et al.. (2010). Gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer. Health Technology Assessment. 14(Suppl 2). 71–79. 15 indexed citations
7.
Greenhalgh, J, A Bagust, Angela Boland, et al.. (2010). Prasugrel for the treatment of acute coronary artery syndromes with percutaneous coronary intervention. Health Technology Assessment. 14(Suppl 1). 31–8. 26 indexed citations
8.
Bagust, A, Angela Boland, Jo Hockenhull, et al.. (2009). Rituximab for the treatment of rheumatoid arthritis. Health Technology Assessment. 13(Suppl 2). 23–29. 7 indexed citations
9.
Greenhalgh, J, A Bagust, Angela Boland, et al.. (2009). Cetuximab for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck. Health Technology Assessment. 13(Suppl 3). 49–54. 8 indexed citations
10.
Greenhalgh, J, A Bagust, Angela Boland, et al.. (2009). Cetuximab for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck. Health Technology Assessment. 13(Suppl 3). 49–54. 47 indexed citations
11.
McLeod, C, A Bagust, Angela Boland, et al.. (2009). Erlotinib for the treatment of relapsed non-small cell lung cancer. Health Technology Assessment. 13(Suppl 1). 41–47. 8 indexed citations
12.
Bagust, A, Angela Boland, Jo Hockenhull, et al.. (2009). Rituximab for the treatment of rheumatoid arthritis. Health Technology Assessment. 13(Suppl 2). 23–29. 48 indexed citations
13.
McLeod, C, A Bagust, Angela Boland, et al.. (2009). Erlotinib for the treatment of relapsed non-small cell lung cancer. Health Technology Assessment. 13(Suppl 1). 41–47. 38 indexed citations
14.
Green, Christopher F., et al.. (1999). Community pharmacists' attitudes to adverse drug reaction reporting. International Journal of Pharmacy Practice. 7(2). 92–99. 41 indexed citations
15.
Back, DJ, et al.. (1988). Evaluation of Committee on Safety of Medicines yellow card reports on oral contraceptive‐drug interactions with anticonvulsants and antibiotics.. British Journal of Clinical Pharmacology. 25(5). 527–532. 78 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Agnes L. F. Chan Breakdown of academic impact, for papers by Frédérique Rousseau Breakdown of academic impact, for papers by Kim Saverno Breakdown of academic impact, for papers by Aimee Faso Breakdown of academic impact, for papers by Kui Huang Breakdown of academic impact, for papers by Trine Lembrecht Jørgensen Breakdown of academic impact, for papers by Lesley Wise Breakdown of academic impact, for papers by Sophie Fédrizzi Breakdown of academic impact, for papers by Sheray N. Chin Breakdown of academic impact, for papers by James Chan
Rankless by CCL
2026